Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 1928-1941

  Waitt, Catriona John ^a   Garner, Paul ^b   Bonnett, Laura Jayne ^a   Khoo, Saye Hock ^a   Else, Laura Jayne ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

ARV; Mother to child transmission; PK

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; EFAVIRENZ; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

BLOOD SAMPLING; BREAST FEEDING; BREAST MILK; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; ELIMINATION HALF-LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY MASS SPECTROMETRY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MATERNAL PLASMA; META ANALYSIS; PRENATAL EXPOSURE; REVIEW; SYSTEMATIC REVIEW; ULTRAVIOLET SPECTROSCOPY;

EID: 84936948308     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv080     Document Type: Review

References (51)

1. WHO/UNAIDS/UNICEF. Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access 2011. Geneva: WHO, 2011. http://www.who.int/hiv/pub/progress_report2011/en/.
2. WHO. Programmatic Update: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Geneva: WHO, 2012. http://apps.who.int/iris/handle/10665/70892.
3. Achievements in public health. Reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006; 55: 592-7.
4. Mofenson LM. Protecting the next generation: eliminating perinatal HIV-1 infection. N Engl J Med 2010; 362: 2316-8.
5. UNAIDS. Report on the Global HIV/AIDS Epidemic. Geneva: UNAIDS, 2010. http://www.unaids.org/globalreport/Global_report.htm.
6. WHO. Guidelines on HIV and Infant Feeding 2010. http://www.who.int/maternal_child_adolescent/documents/9789241599535/en/.
7. Zeh C, Weidle PJ, Nafisa L et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8: e1000430.
8. Fogel J, Li Q, Taha TE et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52: 1069-76.
9. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
10. Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol 2006; 2: 947-60.
11. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. http://handbook.cochrane.org/.
12. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access. Recommendations for a Public Health Approach. Annexe E. Geneva: WHO, 2010.
13. NIH. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Page 227, Table 2. http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf.
14. Spencer L, Liu S, Wang C et al. Intensive etravirine PK and HIV-1 viral load in breast milk and plasma in HIV+ women. In: Abstracts of the Twenty-first Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2014. Abstract 891. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
15. Spencer L, Neely M, Mordwinkin N et al. Intensive PK of zidovudine, lamivudine and atazanavir and HIV-1 viral load in breast milk and plasma in HIV+ women receiving HAART therapy. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 942. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
16. Corbett AH, Kayira D, White NR et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post partum: results of the BAN Study. Antivir Ther 2014; 19: 587-95.
17. Ruff A, Hamzeh F, Lietman P et al. Excretion of zidovudine in human breast milk. In: Abstracts of Thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract L11. American Society for Microbiology, Washington, DC, USA.
18. Colebunders R, Hodossy B, Burger D et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 2005; 19: 1912-5.
19. FDA. Guidance for Industry: Bioanalytical Method Validation. 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
20. Kunz A, Frank M, Mugenyi K et al. Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration. J Antimicrob Chemother 2009; 63: 170-7.
21. Rezk NL, White N, Kashuba AD. An accurate and precise highperformance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. Anal Chim Acta 2008; 628: 204-13.
22. Corbett A, Martinson F, Rezk N et al. Antiretroviral drug concentrations in breast milk and breastfeeding infants. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 648. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
23. Palombi L, Pirillo MF, Andreotti M et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther 2012; 17: 1511-9.
24. Giuliano M, Guidotti G, AndreottiM et al. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr 2007; 44: 286-91.
25. Mirochnick M, Thomas T, Capparelli E et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53: 1170-6.
26. Mirochnick M, Nielsen-Saines K, Pilotto JH et al. Nevirapine concentrations in newborns receiving an extended prophylactic regimen. J Acquir Immune Defic Syndr 2008; 47: 334-7.
27. Schneider S, Peltier A, Gras A et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008; 48: 450-4.
28. Olagunju A, Siccardi M, Okafor O et al. Pharmacogenetics of efavirenz excretion into human breast milk and transfer to breastfed infants. In: Abstracts of the Twenty-first Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2014. Abstract 888. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
29. Moodley J, Moodley D, Pillay K et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-33.
30. Shapiro RL, Holland DT, Capparelli E et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192: 720-7.
31. Rezk NL, White N, Bridges AS et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit 2008; 30: 611-9.
32. Fogel JM, Taha TE, Sun J et al. Stavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants. J Acquir Immune Defic Syndr 2012; 60: 462-5.
33. Mirochnick M, Kafulafula G, Kreitchmann R et al. Pharmacokinetics (PK) of tenofovir disoproxil fumarate (TDF) after administration to HIV-1 infected pregnant women and their newborns. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract T-137. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
34. Benaboud S, Pruvost A, Coffie PA et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011; 55: 1315-7.
35. Anderson PL, Kakuda TN, Kawle S et al. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17: 2159-68.
36. Fletcher CV, Kawle SP, Kakuda TN et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000; 14: 2137-44.
37. Coates JA, Cammack N, Jenkinson HJ et al. (2)-2'-Deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992; 36: 733-9.
38. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Geneva: WHO, 2013. http://www.who.int/hiv/pub/guidelines/arv2013/en/.
39. Acosta EP, Limoli KL, Trinh L et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Agents Chemother 2012; 56: 5938-45.
40. Ford N, Mofenson L, Kranzer K et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010; 24: 1461-70.
41. Abraham MH, Gil-Lostes J, Fatemi M. Prediction of milk/plasma concentration ratios of drugs and environmental pollutants. Eur J Med Chem 2009; 44: 2452-8.
42. Boffito M, Back DJ, Blaschke TF et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19: 825-35.
43. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28: 105-14.
44. Begg EJ, Duffull SB, Hackett LP et al. Studying drugs in human milk: time to unify the approach. J Hum Lact 2002; 18: 323-32.
45. Shapiro RL, Ribaudo H, Powis K et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS 2012; 26: 120-1.
46. Aizire J, McConnell MS, Mudiope P et al. Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single-dose nevirapine. J Acquir Immune Defic Syndr 2012; 60: 483-8.
47. Frank M, Harms G, Kunz A et al. Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission programin Uganda to assess the impact of different dosing regimens for newborns. J Clin Pharmacol 2013; 53: 294-304.
48. Mirochnick M, Fenton T, Gagnier P et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178: 368-74.
49. Mirochnick M, Taha T, Kreitchmann R et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr 2014; 65: 33-41.
50. Musoke P, Guay LA, Bagenda D et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13: 479-86.
51. Weidle PJ, Zeh C, Martin A et al. Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir. Antimicrob Agents Chemother 2011; 55: 5168-71.